Ovarian response to repeated controlled stimulation in in-vitro fertilization cycles in patients with ovarian endometriosis.
In-vitro fertilization (IVF) is an effective infertility treatment for women with endometriosis, but most women need to undergo several cycles of treatment to become pregnant. This case-control study was designed to assess how consistently women with ovarian endometriosis respond to ovarian stimulation in consecutive treatment cycles compared to women with tubal infertility. We compared outcome measures in 40 women with a history of surgically confirmed ovarian endometriosis and 80 women with tubal infertility, all of whom had at least three IVF treatment cycles. The groups were matched for age and early follicular follicle stimulating hormone (FSH) concentration at their first IVF cycle. Outcome measures included number of follicles, number of oocytes, peak oestradiol concentration and number of FSH ampoules required per follicle. Cumulative pregnancy and live birth rates were calculated in both groups. The ovarian endometriosis group had a significantly poorer ovarian response and required significantly more ampoules of FSH per cycle, a difference that became greater with each subsequent cycle. However, cumulative pregnancy (63.3 versus 62.6% by fifth cycle) and live birth (46.8 versus 50.9% by fifth cycle) rates were similar in both groups. In conclusion, despite decreased ovarian response to FSH, ovarian endometriosis does not decrease the chances of successful IVF treatment.
Al-Azemi
M
M
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford Radcliffe Hospital, Women's Centre, Oxford, OX3 9DU, UK.
Bernal
A L
AL
Steele
J
J
Gramsbergen
I
I
Barlow
D
D
Kennedy
S
S
D000328:Adult; D016022:Case-Control Studies; D002452:Cell Count; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D004624:Embryo Transfer; D004715:Endometriosis / Q000150:complications*; D004958:Estradiol / Q000097:blood; D005184:Fallopian Tube Diseases / Q000150:complications; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000628:therapy*; D008596:Menotropins / Q000008:administration & dosage; D017274:Nafarelin / Q000008:administration & dosage; D009865:Oocytes; D010049:Ovarian Diseases / Q000150:complications*; D006080:Ovarian Follicle / Q000187:drug effects; D010062:Ovulation Induction; D011247:Pregnancy; D011446:Prospective Studies
D006063:Chorionic Gonadotropin; D017274:Nafarelin; D004958:Estradiol; D008596:Menotropins; D005640:Follicle Stimulating Hormone